Silo Pharma (SILO) Research & Development (2020 - 2026)
Silo Pharma (SILO) posted Research & Development of $1.0 million for Q1 2026, up 175.81% sequentially from -$1.3 million in Q4 2025, and up 70.59% YoY from $593962.0 in Q1 2025.
Silo Pharma (SILO) Research & Development (2020 - 2026) Analysis & Trends
Silo Pharma has reported Research & Development for 7 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Research & Development rose 70.59% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $937528.0 (down 63.66% YoY) and the FY2025 annual result came in at $518225.0, down 78.12% from the prior year.
- Research & Development grew to $1.0 million in Q1 2026 per SILO's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Research & Development peaked at $1.1 million in Q4 2024 and troughed at -$1.3 million in Q4 2025.
- A 5-year average of $272006.4 and a median of $336965.0 in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 432.94% in 2022, down 266.34% in 2022.
- Over 5 years, Research & Development stood at -$649250.0 in 2022, then surged by 151.9% to $336965.0 in 2023, then jumped by 219.24% to $1.1 million in 2024, then tumbled by 224.25% to -$1.3 million in 2025, then jumped by 175.81% to $1.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.0 million, -$1.3 million, and $543615.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Silo Pharma | 3.04 Mn | 3.04 Mn | - | 298,418.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298,418.00 |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | -1.34 Mn |
| Sep 30, 2025 | 543,615.00 |
| Jun 30, 2025 | 717,247.00 |
| Mar 31, 2025 | 593,962.00 |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 517,548.00 |
| Jun 30, 2024 | 392,824.00 |
| Mar 31, 2024 | 318,240.00 |
| Dec 31, 2023 | 336,965.00 |
| Sep 30, 2023 | 174,495.00 |
| Jun 30, 2023 | 130,719.00 |
| Mar 31, 2023 | 143,608.00 |
| Dec 31, 2022 | -649,250.00 |
| Sep 30, 2022 | 375,795.00 |
| Jun 30, 2022 | 105,676.00 |
| Mar 31, 2022 | 170,279.00 |
| Dec 31, 2021 | -177,225.00 |
| Sep 30, 2021 | 70,514.00 |